Repligen | RGEN - Operating Expenses


Repligen reported $185.01M in Operating Expenses for its fiscal quarter ending in September of 2026.





Operating Expenses Change Date
Agilent USD 1.43B 2M Jun/2026
Align Technology USD 821.72M 43.15M Sep/2026
Bio Techne USD 243.9M 17.7M Sep/2026
BioMarin Pharmaceutical USD 819.04M 5.5B Sep/2026
Bristol-Myers Squibb USD 23.4B 1.08B Sep/2026
Bruker USD 790.5M 21.6M Sep/2026
Charles River Laboratories USD 3.23B 387.38M Sep/2026
Danaher USD 53.62B 1.04B Sep/2026
Dentsply International USD 1.36B 4M Sep/2026
General Electric Aerospace USD 17.52B 118M Sep/2026
Henry Schein USD 3.27B 8M Sep/2026
Illumina USD 525M 374M Sep/2026
IQVIA Holdings USD 3.82B 2.05B Sep/2026
Mettler Toledo International USD 77.66M 662.11M Sep/2026
Myriad Genetics USD 212.8M 16.2M Dec/2025
OraSure Technologies USD 40.35M 2.45M Dec/2025
Pacific Biosciences Of California USD 97.83M 41.29M Dec/2025
Pfizer USD 89B 3.81B Sep/2026
Repligen USD 185.01M 2.01M Sep/2026
Revvity USD 604.27M 719K Sep/2026
Standard Biotools USD 27.93M 2.63M Jun/2026
Thermo Fisher Scientific USD 9.68B 134M Sep/2026
Waters USD 527M 592M Jun/2026
West Pharmaceutical Services USD 2.97B 22M Sep/2026